JPWO2025170079A1 - - Google Patents

Info

Publication number
JPWO2025170079A1
JPWO2025170079A1 JP2025540402A JP2025540402A JPWO2025170079A1 JP WO2025170079 A1 JPWO2025170079 A1 JP WO2025170079A1 JP 2025540402 A JP2025540402 A JP 2025540402A JP 2025540402 A JP2025540402 A JP 2025540402A JP WO2025170079 A1 JPWO2025170079 A1 JP WO2025170079A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025540402A
Other languages
Japanese (ja)
Other versions
JPWO2025170079A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2025170079A1 publication Critical patent/JPWO2025170079A1/ja
Publication of JPWO2025170079A5 publication Critical patent/JPWO2025170079A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2025540402A 2024-02-09 2025-02-10 Pending JPWO2025170079A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2024018774 2024-02-09
PCT/JP2025/004430 WO2025170079A1 (ja) 2024-02-09 2025-02-10 慢性炎症を抑制するための医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2025170079A1 true JPWO2025170079A1 (https=) 2025-08-14
JPWO2025170079A5 JPWO2025170079A5 (https=) 2026-01-15

Family

ID=96700007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025540402A Pending JPWO2025170079A1 (https=) 2024-02-09 2025-02-10

Country Status (2)

Country Link
JP (1) JPWO2025170079A1 (https=)
WO (1) WO2025170079A1 (https=)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516672A (ja) * 2013-02-28 2016-06-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 幹細胞を動員するための方法および組成物
WO2019073999A1 (ja) * 2017-10-13 2019-04-18 マイクロニクス株式会社 細胞内液精製システム、細胞内液精製方法、炎症性腸疾患の予防剤、改善剤または治療剤、あるいは、精子活性化剤、もしくは、化粧品成分を製造する製造方法、炎症性腸疾患の予防剤、改善剤または治療剤、および、精子活性化剤の製造方法
JP2020534247A (ja) * 2017-06-30 2020-11-26 エクソコバイオ インコーポレイテッド 脂肪由来幹細胞由来のエキソソームを有効成分として含む組成物の皮膚炎の改善の用途
JP2021116257A (ja) * 2020-01-27 2021-08-10 国立大学法人旭川医科大学 下部尿路機能障害の治療
JP2021528984A (ja) * 2018-07-02 2021-10-28 リン、シー−ランLIN, Shi−Lung 成体幹細胞の拡大と誘導のインビトロでの誘発
JP2022027930A (ja) * 2018-07-04 2022-02-14 正典 佐伯 幹細胞濾液製剤及びその調製方法
JP2022045325A (ja) * 2020-09-08 2022-03-18 デクソンファーマシューティカルズ株式会社 サイトカインストーム抑制剤、サイトカインストーム抑制剤の使用方法およびスクリーニング方法
WO2022180661A1 (ja) * 2021-02-24 2022-09-01 株式会社Meis Technology 変形性関節症又は靭帯若しくは腱の治療製剤、及びその製造方法。
JP2023533556A (ja) * 2020-07-10 2023-08-03 シャリテ－ウニヴェルジテーツメディツィン・ベルリン 心臓修復のためのマイクロｒｎａ標的療法
JP2023139438A (ja) * 2022-03-22 2023-10-04 Ｄｅｘｏｎファーマシューティカルズ株式会社 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
JP2024000505A (ja) * 2022-06-20 2024-01-05 Ｄｅｘｏｎファーマシューティカルズ株式会社 Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025285A1 (en) * 2016-05-25 2017-11-30 Erasmus University Medical Center Rotterdam Use of mesenchymal stem cells and parts thereof
KR102193175B1 (ko) * 2020-04-07 2020-12-18 주식회사 엑소스템텍 통증조절인자를 함유한 줄기세포유래 엑소좀 및 그 용도
JP2023144863A (ja) * 2022-03-28 2023-10-11 Ｄｅｘｏｎファーマシューティカルズ株式会社 微小粒子、パーキンソン病の予防薬または治療薬およびパーキンソン病の改善方法
JP2023155686A (ja) * 2022-04-11 2023-10-23 Ｄｅｘｏｎファーマシューティカルズ株式会社 微小粒子、血管新生眼疾患の予防薬または治療薬および血管新生眼疾患の改善方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516672A (ja) * 2013-02-28 2016-06-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 幹細胞を動員するための方法および組成物
JP2020534247A (ja) * 2017-06-30 2020-11-26 エクソコバイオ インコーポレイテッド 脂肪由来幹細胞由来のエキソソームを有効成分として含む組成物の皮膚炎の改善の用途
WO2019073999A1 (ja) * 2017-10-13 2019-04-18 マイクロニクス株式会社 細胞内液精製システム、細胞内液精製方法、炎症性腸疾患の予防剤、改善剤または治療剤、あるいは、精子活性化剤、もしくは、化粧品成分を製造する製造方法、炎症性腸疾患の予防剤、改善剤または治療剤、および、精子活性化剤の製造方法
JP2021528984A (ja) * 2018-07-02 2021-10-28 リン、シー−ランLIN, Shi−Lung 成体幹細胞の拡大と誘導のインビトロでの誘発
JP2022027930A (ja) * 2018-07-04 2022-02-14 正典 佐伯 幹細胞濾液製剤及びその調製方法
JP2021116257A (ja) * 2020-01-27 2021-08-10 国立大学法人旭川医科大学 下部尿路機能障害の治療
JP2023533556A (ja) * 2020-07-10 2023-08-03 シャリテ－ウニヴェルジテーツメディツィン・ベルリン 心臓修復のためのマイクロｒｎａ標的療法
JP2022045325A (ja) * 2020-09-08 2022-03-18 デクソンファーマシューティカルズ株式会社 サイトカインストーム抑制剤、サイトカインストーム抑制剤の使用方法およびスクリーニング方法
WO2022180661A1 (ja) * 2021-02-24 2022-09-01 株式会社Meis Technology 変形性関節症又は靭帯若しくは腱の治療製剤、及びその製造方法。
JP2023139438A (ja) * 2022-03-22 2023-10-04 Ｄｅｘｏｎファーマシューティカルズ株式会社 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
JP2024000505A (ja) * 2022-06-20 2024-01-05 Ｄｅｘｏｎファーマシューティカルズ株式会社 Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
YASUYUKI FUJITA ET AL.: "Vascular and Tissue Regeneration by CD34+ Cells", PEDIATRIC CARDIOLOGY AND CARDIAC SURGERY, vol. 31, JPN6025019007, 2015, pages 80 - 87, ISSN: 0005840642 *
YUJI TOMINAGA ET AL.: "Pleiotropic effects of extracellular vesicles from induced pluripotent stem cell-derived cardiomyocy", THE JOURNAL OF HEART AND LUNG TRANSPLANTATION, vol. 43, JPN6025019008, 2024, pages 85 - 99, ISSN: 0005840640 *
増田篤高 他: "WS9-9 培養CD34陽性細胞移植は炎症性ケモカインCXCL9/10を抑制することでNASHを改善させる", 肝臓, vol. 第63巻, supp1. (1), JPN6025019010, 2022, pages 176, ISSN: 0005840641 *

Also Published As

Publication number Publication date
WO2025170079A1 (ja) 2025-08-14

Similar Documents

Publication Publication Date Title
CN309951950S (zh) 梳子（镂空折叠梳）
JPWO2025170079A1 (https=)
FR3168252A1 (fr) Dispositif lumineux à néon flexible
CN308699399S (https=)
CN309686661S (https=)
CN309567128S (https=)
CN308408743S (https=)
CN308430712S (https=)
CN308408815S (https=)
CN308408522S (https=)
CN308403329S (https=)
CN308408272S (https=)
CN308407776S (https=)
CN308403167S (https=)
CN308407774S (https=)
CN308430581S (https=)
CN309652964S (https=)
CN308407232S (https=)
CN309613887S (https=)
CN309539776S (https=)
CN309428813S (https=)
CN309384496S (https=)
CN309375106S (https=)
CN308878310S (https=)
CN308412863S (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250709

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250709

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20250718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260415